SECISBP2L (SECIS binding protein 2 like) functions as an RNA-binding protein that binds to SECIS (Sec insertion sequence) elements in selenocysteine protein mRNAs, though it does not promote selenocysteine incorporation into selenoproteins in vitro. The protein localizes to mitochondria and participates in ribonucleoprotein complex formation. SECISBP2L has emerged as a disease-relevant gene through multiple genetic association studies. Large-scale GWAS analysis identified SECISBP2L as a candidate gene associated with lung cancer susceptibility, particularly lung adenocarcinoma 1. Cross-trait genetic analyses revealed SECISBP2L among genes significantly associated with headache-thyroid function relationships, specifically in headache-free thyroxine correlations 2. In acute myeloid leukemia, SECISBP2L was identified as part of a highly interconnected gene network associated with treatment response and prognosis 3. Additionally, in lung squamous cell carcinoma, SECISBP2L functions as a prognostic RNA-binding protein gene, with regulatory networks involving angiogenesis pathways and multiple target RNAs including ADGRF5, TGFBR2, and CD302 4. These findings suggest SECISBP2L plays important roles in cancer biology and may serve as a biomarker for disease susceptibility and prognosis across multiple conditions.